<b>Background:</b> Tyrosine kinase inhibitors (TKIs) are standard treatment options for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (<i>EGFR</i>) mutations. Here, EGFR is linked to non-small cell lung carcinoma.